Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Josep Maria Cendrós"'
Publikováno v:
Veterinary Medicine and Science, Vol 8, Iss 1, Pp 31-45 (2022)
Abstract Enflicoxib is a newly developed NSAID of the coxib class. The optimal therapeutic dose to be confirmed in the field studies was established using a combination of pharmacokinetic (PK) modelling and pharmacodynamic (PD) studies. First, a PK s
Externí odkaz:
https://doaj.org/article/3964c3804fb44396812d9e5b21933afd
Autor:
Helena Colom, Annabel Blasi, Bruno Montoro, Angel‐Guillermo Arévalo, Josep Maria Cendrós, Antoni Sabaté
Publikováno v:
British Journal of Clinical Pharmacology.
Publikováno v:
Veterinary Medicine and Science, Vol 8, Iss 1, Pp 31-45 (2022)
Veterinary Medicine and Science
Veterinary Medicine and Science
Enflicoxib is a newly developed NSAID of the coxib class. The optimal therapeutic dose to be confirmed in the field studies was established using a combination of pharmacokinetic (PK) modelling and pharmacodynamic (PD) studies. First, a PK study was
Autor:
Josep Solà, Angel Menargues, Marta Salichs, Gregorio Encina, Josep-Maria Cendrós, Josep Homedes
Publikováno v:
Journal of Veterinary Pharmacology and Therapeutics. 44:888-901
The pharmacokinetics of enflicoxib were evaluated in both a bioavailability study and a multi-dose safety study in Beagle dogs. When administered at 8 mg/kg, the oral bioavailability (F) of enflicoxib was 44.1% in fasted dogs, but F increased to 63.4